600566.SS
Strong BuyFull HouseAI neutralHubei Jumpcan Pharmaceutical Co., Ltd. · Healthcare · China · $3.4B
CNY 25.63 +3.1% · close 30 Sep · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Despite positive EPS revisions and an active buyback, the occurrence of net insider selling, however small, necessitates a flag based on the rigorous 'No Adverse Evidence' standard.
ABOUT HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.
Read
Hubei Jumpcan Pharmaceutical Co., Ltd. manufactures and distributes pediatric medicines, Traditional Chinese Medicine, and chemical drugs. The company holds a leading position in China's pediatric TCM market, with its flagship pediatric bronchodilator enjoying high brand loyalty and clinical prescription rates. It is a highly specialized pharmaceutical company with a dominant niche in pediatric healthcare.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 9.0B | 9.7B | 8.0B | 6.2B | -11.6% | 5.8B |
| EPS (CNY) | 2.44 | 3.08 | 2.76 | 1.93 | -7.5% | 2.00 |
| Shares | 921.8M | 921.8M | 921.7M | 921.3M | -0.1% | 921.8M |
| Debt | 400.6M | 1.0B | 789.3M | 765.5M | 24.1% | 1.5B |
| Equity | 11.3B | 13.3B | 14.7B | 14.6B | 8.8% | — |
| Op CF | 2.6B | 3.5B | 2.2B | 1.2B | -23.0% | 1.1B |
| Inv CF | -1.5B | -394.2M | -2.0B | -976.3M | — | — |
| Fin CF | -117.6M | -150.7M | -1.2B | -1.5B | — | — |
Calmer than 75% of stocks we rank over the past year (28% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600566.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 600566.SS | Hubei Jumpcan Pharmaceutical Co., Ltd.(you) | $3.4B | 96 | Strong Buy |
| 2096.HK | Simcere Pharmaceutical Group Limited | $3.7B | 97 | Strong Buy |
| 600535.SS | Tasly Pharmaceutical Group Co., Ltd | $3.0B | 94 | Strong Buy |
| 1513.HK | Livzon Pharmaceutical Group Inc. | $2.4B | 96 | Strong Buy |
| 000423.SZ | Dong-E-E-Jiao Co., Ltd. | $4.3B | 94 | Strong Buy |
| 002603.SZ | Shijiazhuang Yiling Pharmaceutical Co., Ltd. | $3.8B | 91 | Strong Buy |
| 600380.SS | Joincare Pharmaceutical Group Industry Co.,Ltd. | $2.5B | 90 | Strong Buy |
| 600267.SS | Zhejiang Hisun Pharmaceutical Co., Ltd. | $2.0B | 94 | Strong Buy |
| 600750.SS | China Resources Jiangzhong Pharmaceutical Co.,Ltd | $2.1B | 90 | Strong Buy |
| 000999.SZ | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | $5.8B | 91 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 52.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.